Luminex Corporation Begins Clinical Trials for ARIES™ GBS Assay

AUSTIN, Texas, June 8, 2015 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has commenced clinical and analytical studies to evaluate the company's ARIES™ Group B Streptococcus (GBS) Assay.

"We continue to build momentum in our commercial launch schedule for the ARIES platform with the start of clinical trials for GBS, the third assay in the ARIES pipeline," said Homi Shamir, President and CEO of Luminex. "The progression of our ARIES menu with assays that are important to patient care continues and the Group B Strep assay is a key contributor due to the high prevalence and potentially serious or life threatening consequences to newborns."

The clinical trials for the ARIES GBS Assay are being conducted at several clinical laboratories in the U.S., and Luminex still expects its FDA submission for the ARIES platform and ARIES HSV 1&2 Assay to occur in the summer of 2015.

About Group B Streptococcus (GBS)

One in four pregnant women are colonized with Group B Streptococcus (GBS), also known as Streptococcus agalactiae. If not treated, GBS can be transmitted to a newborn during labor and delivery, potentially resulting in sepsis, pneumonia, or meningitis. Fortunately, most GBS infections can be prevented through recommended prenatal screening and, if positive, administration of antibiotic treatment during delivery.¹

About ARIES

ARIES is a sample to answer system designed to deliver superior laboratory performance, increase laboratory efficiency, and fit seamlessly into today's lean laboratory environment. ARIES uses internal barcode scanning and other advanced features to minimize operator errors. Two independent magazine modules support from one to six cassettes each, allowing for STAT and Batch testing. Simultaneous IVD and Laboratory Developed Tests (LDTs) operate through a common Universal Assay Protocol. An integrated PC eliminates the need for a separate computer, stand-alone keyboard, and mouse, thus maximizing valuable bench space.

To learn more or request a demo, visit: http://www.luminexcorp.com/ARIES

About Luminex Corporation

Luminex is committed to applying its passion for innovation toward creating breakthrough solutions to improve health and advance science. The company is transforming global healthcare and life-science research through the development, manufacturing and marketing of proprietary instruments and assays utilizing xMAP® open-architecture multi-analyte platform, MultiCode® real-time polymerase chain reaction (PCR), and multiplex PCR-based technologies, that deliver cost-effective rapid results to clinicians and researchers. Luminex's technology is commercially available worldwide and in use in leading clinical laboratories, as well as major pharmaceutical, diagnostic, biotechnology, and life science companies. Luminex is meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, biodefense research and food safety. For further information on Luminex Corporation and the latest advances in multiplexing using award winning technology, please visit http://www.luminexcorp.com/.

Statements made in this release that express Luminex's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. Forward-looking statements in this release include statements regarding the development and testing progress of our pipeline products, including ARIES and related assays, and the regulatory approvals thereof. The words "believe", "expect", "intend", "confident", "will", "could", "should", and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results or performance could differ materially from those anticipated in such forward-looking statements. Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, our ability to launch products on time, the timing of regulatory approvals, the outcome of clinical trials as well as the risks discussed under the heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission. The forward-looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

References:

1. About Group B Strep. Centers for Disease Control and Prevention (Internet). Cited 2015 June.  Available from: http://www.cdc.gov/groupbstrep/about.

Contacts:

Luminex Investor Contact
Harriss Currie, 512.219.8020
Sr. Vice President of Finance and CFO
[e-mail]

Luminex Media Contact
Christine Valle, 512.219.8020
Sr. Manager, Global Marketing
[e-mail]

Photo - http://photos.prnewswire.com/prnh/20150608/221405
Logo - http://photos.prnewswire.com/prnh/20150201/172702LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/luminex-corporation-begins-clinical-trials-for-aries-gbs-assay-300095514.html

SOURCE Luminex Corporation

Copyright 2015 PR Newswire